News | News By Subject | News by Disease News By Date | Search News

Acute Coronary Syndrome News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Startup with Bay Area Ties, DalCor, Secures $150 Million Financing and to Launch Phase III Trial     4/19/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod     6/9/2014
GlaxoSmithKline (GSK)'s Once Promising Heart Drug Strikes Out Again     5/14/2014
FDA Rejects Wider Use Of Bayer AG (BAYN.DE)'s Xarelto Drug For Acute Coronary Syndrome     2/14/2014
FDA Panel Once Again Rejects Wider Use Of Johnson & Johnson (JNJ) Drug     1/17/2014
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial     1/2/2014
FDA Rejects Johnson & Johnson (JNJ)'s Xarelto Again for ACS     3/7/2013
Merck & Co., Inc. (MRK) on Track to Seek Approval for Two Heart Drugs in ’13     8/27/2012
FDA Panel Votes Against New Use for Johnson & Johnson (JNJ)'s Xarelto     5/25/2012
Bayer HealthCare (BAY)'s Xarelto Granted Priority Review by FDA to Prevent Secondary Cardiovascular Events     2/28/2012
FDA Issues Import Alerts for 22 Chinese Heparin Suppliers     2/24/2012
Johnson & Johnson (JNJ), Bayer AG (BAY.F) Anticlotting Drug Shows Promise in Heart-Attack Patients     11/14/2011

News from Around the Web

Press Releases
Galapagos (GLPG.BR) Release: Orphan Drug Designation In European Union For GLPG1690 In Idiopathic Pulmonary Fibrosis     9/6/2016
DalCor Randomizes First Patient In The DalGenE Phase 3 Cardiovascular Outcomes Trial     4/26/2016
Regeneron (REGN) And Sanofi (SNY) Announce 18,000-Patient ODYSSEY OUTCOMES Trial Of Praluent Injection Fully Enrolled     11/24/2015
Resverlogix Corporation (RVX.TO) Release: Leading Life Science Publication SciBX Highlights RVX-208     5/21/2014
AstraZeneca PLC (AZN) Release: New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)     7/31/2013
Stealth Peptides Inc. Reports Successful Clinical Study of Oral Bendavia     1/22/2013
XOMA Corporation (XOMA) Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome     11/29/2012
AstraZeneca PLC (AZN) Release: New PLATO Analysis Evaluates the Influence of High-Sensitivity Troponin Biomarker Status in NSTE-ACS Patients Managed With Revascularization or Medical Management     11/7/2012
Medicure Inc. (MCU) Announces Development of Novel Aggrastat Formulation     9/26/2012
AstraZeneca PLC (AZN) Release: New European Society of Cardiology Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients With ST-Elevation     8/28/2012
Boehringer Ingelheim Corporation Release: No Significant Difference in the Risk of Acute Coronary Syndrome (including Myocardial Infarction) Seen With Pradaxa®(dabigatran etexilate) Compared to Enoxaparin for VTE Prevention After Orthopaedic Surgery     6/25/2012
AstraZeneca PLC (AZN) Announces Increased Coverage of BRILINTA (Ticagrelor) Through Plan Preferred Formulary Status on Medco Health Solutions, Inc.     3/22/2012
BG Medicine Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)     11/30/2011
AstraZeneca PLC (AZN) Release: BRILINTA™ (ticagrelor) Tablets Now Available in U.S. Pharmacies for Patients with Acute Coronary Syndrome     8/22/2011
Cerenis Therapeutics, Inc. Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome     3/15/2011

//-->